Veronica Santini
Neurology · New Haven, CTNPI 1508097742
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 69.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $4,384 and has fallen 98.6% since, to $63 in 2025.
Across 18 payments — averaging $352.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$4K
- Lundbeck LLC$1K
- Medtronic$466
- Amneal Pharmaceuticals LLC$104
- Acadia Pharmaceuticals Inc$64
Across 24 payments — averaging $4043.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$97K
What the payments were for
- Consulting fees$3,60057%
- Speaking & faculty fees$1,30020%
- Travel & lodging$76812%
- Food & beverage$67511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 8 | $4,410 |
| Lundbeck LLC | 1 | $1,300 |
| Medtronic(2 entities) | 7 | $466 |
| Amneal Pharmaceuticals LLC | 1 | $104 |
| Acadia Pharmaceuticals Inc | 1 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,344 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $93,015 |
| Droxidopa | 14 | $39,504 |
| RytaryCarbidopa/Levodopa | 27 | $30,828 |
| NeuproRotigotine | 20 | $18,341 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 345 | $9,560 |
| Rasagiline Mesylate | 52 | $7,485 |
| Carbidopa | 26 | $5,075 |
| Selegiline Hcl | 24 | $3,725 |
| Entacapone | 15 | $3,550 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 109 | $2,873 |
| AmantadineAmantadine Hcl | 58 | $2,453 |
| Midodrine Hcl | 17 | $2,235 |
| Primidone | 83 | $1,656 |
| Fludrocortisone Acetate | 48 | $1,418 |
| Gabapentin | 73 | $1,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $4,410 | $93,01512 claims |
| Amneal Pharmaceuticals LLCRytary | $104 | $30,82827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.
Other neurology in New Haven
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- David RussellNew Haven$208K
- Richard NowakNew Haven$126K
- David HaflerNew Haven$118K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.